Recent Finacing
Recent Raise
NexImmune develops nanoparticle-based artificial antigen-presenting cell (aAPC) therapies using its AIM platform to enrich, activate, and expand endogenous CD8+ T cells for hematologic cancers, advancing clinical-stage development.
